The number of antibiotic-resistant gonorrhea cases continues to rise across Europe. While such infections were previously mainly associated with overseas travel, specialists have noted their active spread within European countries since 2025. The most significant increase has been recorded in France, Germany, Sweden, and the United Kingdom. Isolated cases continue to be identified in other countries as well. According to experts from the ECDC, it is particularly concerning that the bacteria are becoming less sensitive to ceftriaxone—the primary drug for treating gonorrhea—as well as to azithromycin, which is often used in combination therapy. If resistance continues to grow, the options for effective treatment will gradually diminish. According to specialists, most resistant strains still enter Europe from Southeast Asian countries, including Cambodia, Indonesia, Thailand, and Vietnam. However, local transmission of the infection is increasingly being reported, indicating the onset of its independent spread in Europe. Gonorrhea remains one of the most common bacterial sexually transmitted infections. Without timely treatment, the disease can lead to pelvic inflammatory disease, infertility, and ectopic pregnancy. According to the ECDC, the gonorrhea incidence rate in EU countries has increased by 303% over the past decade. In 2024, there were 106,331 confirmed cases—this is the highest figure since European epidemiological surveillance began in 2009. Specialists note that the increase is due not only to a rise in the number of infections but also to broader testing of the population. The ECDC believes that the overall risk to the population remains low for now. However, individuals with multiple sexual partners, those practicing unprotected sex, or traveling to regions with a high prevalence of resistant strains are advised to take preventive measures, use protection, and undergo timely testing and treatment when necessary.